Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO• and beyond

Pharmacology and Therapeutics

Volumn 124, Issue 3, 2009, Pages 279-300

  Ritchie, Rebecca H ^a   Irvine, Jennifer C ^a   Rosenkranz, Anke C ^b   Patel, Ruchi ^c   Wendt, Igor R ^d   Horowitz, John D ^e   Kemp Harper, Barbara K ^d  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Institut für Pharmacoloie and Klinische Pharmakologie   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cardiomyocyte; Cyclic GMP; Guanylyl cyclase; Myocardium; Natriuretic peptides; Nitric oxide

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CARBON MONOXIDE; CARDIOVASCULAR AGENT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LOSARTAN; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NATRIURETIC FACTOR; NESIRITIDE; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; SORAFENIB; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CELL DEATH; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; NEUROMODULATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME; VASODILATATION;

CARBON MONOXIDE; CARDIOVASCULAR SYSTEM; CYCLIC GMP; GUANYLATE CYCLASE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; NATRIURETIC PEPTIDES; NITRIC OXIDE DONORS; PHOSPHODIESTERASE INHIBITORS;

EID: 70449718779     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.08.001     Document Type: Review

References (418)

1. Abraham N.G., and Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharm Rev 60 (2008) 79-127
2. Abrams J. How to use nitrates. Cardiovasc Drugs Ther 16 (2002) 511-514
3. Achouh P.E., Simonet S., Fabiani J.N., and Verbeuren T.J. Carbon monoxide induces relaxation of human internal thoracic and radial arterial grafts. Interact Cardiovasc Thorac Surg 7 6 (2008) 959-962
4. Adiga I.K., and Nair R.R. Multiple signaling pathways coordinately mediate reactive oxygen species dependent cardiomyocyte hypertrophy. Cell Biochem Funct 26 3 (2008) 346-351
5. Aikawa R., Nagai T., Kudoh S., Zou Y., Tanaka M., Tamura M., Akazawa H., Takano H., Nagai R., and Komuro I. Integrins play a critical role in mechanical stress-induced p38 MAPK activation. Hypertension 39 2 (2002) 233-238
6. Akazawa H., and Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 92 10 (2003) 1079-1088
7. Andrews K., Irvine J., Tare M., Aposolopoulos J., Favaloro J., Triggle C., and Kemp-Harper B. A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarising factor in resistance arteries. Br J Pharmacol 157 4 (2009) 540-550
8. Anfossi G., Russo I., Massucco P., Mattiello L., Doronzo G., De Salve A., and Trovati M. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 34 7 (2004) 482-489
9. Angelis E., Tse M.Y., and Pang S.C. Interactions between atrial natriuretic peptide and the renin-angiotensin system during salt-sensitivity exhibited by the proANP gene-disrupted mouse. Mol Cell Biochem 276 1-2 (2005) 121-131
10. Antos C.L., McKinsey T.A., Frey N., Kutschke W., McAnally J., Shelton J.M., Richardson J.A., Hill J.A., and Olson E.N. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 99 2 (2002) 907-912
11. Arjona A.A., Hsu C.A., Wrenn D.S., and Hill N.S. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol 28 3 (1997) 387-392
12. Armstrong P.W., Armstrong J.A., and Marks G.S. Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac-failure. Circulation 62 1 (1980) 160-166
13. Arora R.R., Venkatesh P.K., and Molnar J. Short and long-term mortality with nesiritide. Am Heart J 152 (2006) 1084-1090
14. Arstall M.A., Yang J.F., Stafford I., Betts W.H., and Horowitz J.D. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial-infarction - safety and biochemical effects. Circulation 92 10 (1995) 2855-2862
15. Asirvatham S., Sebastian C., and Thadani U. Choosing the most appropriate treatment for stable angina. Safety considerations. Drug Safety 19 1 (1998) 23-44
16. Babbitt C.J., Shai S.Y., Harpf A.E., Pham C.G., and Ross R.S. Modulation of integrins and integrin signaling molecules in the pressure-loaded murine ventricle. Histochem Cell Biol 118 6 (2002) 431-439
17. Baker K.M., Chernin M.I., Wixson S.K., and Aceto J.F. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259 2 Pt 2 (1990) H324-332
18. Barouch L.A., Harrison R.W., Skaf M.W., Rosas G.O., Cappola T.P., Kobeissi Z.A., Hobai I.A., Lemmon C.A., Burnett A.L., O'Rourke B., Rodriguez E.R., Huang P.L., Lima J.A., Berkowitz D.E., and Hare J.M. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416 6878 (2002) 337-339
19. Bayer A.L., Heidkamp M.C., Patel N., Porter M., Engman S., and Samarel A.M. Alterations in protein kinase C isoenzyme expression and autophosphorylation during the progression of pressure overload-induced left ventricular hypertrophy. Mol Cell Biochem 242 1-2 (2003) 145-152
20. Bell R.M., Maddock H.L., and Yellon D.M. The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc Res 57 2 (2003) 405-415
21. Bell J.P., Mosfer S.I., Lang D., Donaldson F., and Lewis M.J. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am J Physiol 281 4 (2001) H1704-1710
22. Bennett B.M., McDonald B.J., Nigam R., and Simon W.C. Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol Sci 15 (1994) 245-249
23. Beretta M., Gruber K., Kollau A., Russwurm M., Koesling D., Goessler W., Keung W.M., Schmidt K., and Mayer B. Bioactivation of nitroglycerin by purified mitochondrial and cytosolic aldehyde dehydrogenases. J Biol Chem 283 26 (2008) 17873-17880
24. Biel M., Zong X.G., Ludwig A., Sautter A., and Hofmann F. Molecular cloning and expression of a modulatory subunit of the cyclic nucleotide-gated cation channel. J Biol Chem 271 11 (1996) 6349-6355
25. Bikkina M., Larson M.G., and Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. J Am Coll Cardiol 22 4 (1993) 1111-1116
26. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., Lapp H., Stasch J.P., and Burnett J.C. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 49 5 (2007) 1128-1133
27. Boerrigter G., Costello-Boerrigter L.C., Cataliotti A., Tsuruda T., Harty G.J., Lapp H., Stasch J.P., and Burnett J.C. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107 5 (2003) 686-689
28. Bogoyevitch M.A., Andersson M.B., Gillespie-Brown J., Clerk A., Glennon P.E., Fuller S.J., and Sugden P.H. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J 314 Pt 1 (1996) 115-121
29. Bogoyevitch M.A., Fuller S.J., and Sugden P.H. cAMP and protein synthesis in isolated adult rat heart preparations. Am J Physiol 265 5 (1993) C1247-C1257
30. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 33 11 (2001) 1897-1918
31. Bolotina V.M., Najibi S., Palacino J.J., Pagano P.J., and Cohen R.A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 368 6474 (1994) 850-853
32. Booz G.W. Putting the brakes on cardiac hypertrophy - exploiting the NO-cGMP counter-regulatory system. Hypertension 45 3 (2005) 341-346
33. Brunner F., Maier R., Andrew P., Wolkart G., Zechner R., and Mayer B. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 57 1 (2003) 55-62
34. Bubikat A., De Windt L.J., Zetsche B., Fabritz L., Sickler H., Eckardt D., Godecke A., Baba H.A., and Kuhn M. Local atrial natriuretic peptide signaling prevents hypertensive cardiac hypertrophy in endothelial nitric-oxide synthase-deficient mice. J Biol Chem 280 22 (2005) 21594-21599
35. Bueno O.F., and Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91 9 (2002) 776-781
36. Bueno O.F., De Windt L.J., Lim H.W., Tymitz K.M., Witt S.A., Kimball T.R., and Molkentin J.D. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo. Circ Res 88 1 (2001) 88-96
37. Burley D.S., and Baxter G.F. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 102 6 (2007) 529-541
38. Burley D.S., Ferdinandy P., and Baxter G.F. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 152 6 (2007) 855-869
39. Burley D.S., Hamid S.A., and Baxter G.F. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 12 3-4 (2007) 279-291
40. Butt E. cGMP-dependent protein kinase modulators. Handb Exp Pharmacol 191 (2009) 409-422
41. Butt E., Geiger J., Jarchau T., Lohmann S.M., and Walter U. The cGMP-dependent protein-kinase - gene, protein, and function. Neurochem Res 18 1 (1993) 27-42
42. Cahill P., and Hassid A. Clearance receptor-binding atrial natriuretic peptides inhibit mitogenesis and proliferation of rat aortic smooth muscle cells. Biochem Biophys Res Commun 3 (1991) 1606-1613
43. Calderone A., Thaik C.M., Takahashi N., Chang D.L., and Colucci W.S. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101 4 (1998) 812-818
44. Campbell D.L., Stamler J.S., and Strauss H.C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108 (1996) 277-293
45. Casteel D.E., Zhang T., Zhuang S.H., and Pilz R.B. cGMP-dependent protein kinase anchoring by IRAG regulates its nuclear translocation and transcriptional activity. Cell Signal 20 7 (2008) 1392-1399
46. Castro L.R.V., Verde I., Cooper D.M.F., and Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113 18 (2006) 2221-2228
47. Cataliotti A., Chen H.H., James K.D., and Burnett J.C. Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. Trends Cardiovasc Med 17 1 (2007) 10-14
48. Cataliotti A., Chen H.H., Schirger J.A., Martin F.L., Boerrigter G., Costello-Boerrigter L.C., James K.D., Polowy K., Miller M.A., Malkar N.B., Bailey K.R., and Burnett J.C. Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension. Circulation 118 17 (2008) 1729-1736
49. Cave A., Grieve D., Johar S., Zhang M., and Shah A.M. NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond B Biol Sci 360 1464 (2005) 2327-2334
50. Cerra M.C., and Pellegrino D. Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr Med Chem 14 5 (2007) 585-599
51. Chang B.S., and Huang S.C. Natriuretic peptides cause relaxation of human esophageal mucosal muscle. Reg Peptides 146 1-3 (2008) 224-229
52. Chen H.H., and Burnett J.C. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 111 5 (1999) 406-416
53. Chen Z., Foster M.W., Zhang J., Mao L., Rockman H.A., Kawamoto T., Kitagawa K., Nakayama K.I., Hess D.T., and Stamler J.S. An essential role for mitochondrial aldehyde dehydrogenase in nitroglycerin bioactivation. Proc Natl Acad Sci U S A 102 34 (2005) 12159-12164
54. Chen Z., Zhang J., and Stamler J.S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 99 12 (2002) 8306-8311
55. Cheng T.H., Shih N.L., Chen S.Y., Lin J.W., Chen Y.L., Chen C.H., Lin H., Cheng C.F., Chiu W.T., Wang D.L., and Chen J.J. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmaco 68 4 (2005) 1183-1192
56. Cheong E., Tumbev V., Abramson J., Salama G., and Stoyanovsky D.A. Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium 37 (2005) 87-96
57. Chesnais J.M., Fischmeister R., and Mery P.F. Peroxynitrite is a positive inotropic agent in atrial and ventricular fibres of the frog heart. J Physiol 521 2 (1999) 375-388
58. Chien K.R., Knowlton K.U., Zhu H., and Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5 15 (1991) 3037-3046
59. Chirkov Y.Y., Chirkova L.P., and Horowitz J.D. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am J Cardiol 80 2 (1997) 128-131
60. Chirkov Y.Y., Holmes A.S., Chirkova L.P., and Horowitz J.D. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation 100 2 (1999) 129-134
61. Chirkov Y.Y., Holmes A.S., Willoughby S.R., Stewart S., and Horowitz J.D. Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. Am J Cardiol 90 5 (2002) 551-554
62. Chirkov Y.Y., Holmes A.S., Willoughby S.R., Stewart S., Wuttke R.D., Sage P.R., and Horowitz J.D. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol 37 7 (2001) 1851-1857
63. Chirkov Y.Y., and Horowitz J.D. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier?. Pharmacol Ther 116 2 (2007) 287-305
64. Chirkov Y.Y., and Horowitz J.D. N-acetylcysteine potentiates nitroglycerin-induced reversal of platelet aggregation. J Cardiovasc Pharmacol 28 3 (1996) 375-380
65. Chong S., and Fung H.L. Kinetic mechanisms for the concentration dependency of in vitro degradation of nitroglycerin and glyceryl dinitrates in human blood: metabolite inhibition or cosubstrate depletion?. J Pharm Sci 78 4 (1989) 295-302
66. Cohen R.A., and Adachi T. Nitric-oxide-induced vasodilatation: regulation by physiologic S-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc Med 16 4 (2006) 109-114
67. Colomer J.M., and Means A.R. Chronic elevation of calmodulin in the ventricles of transgenic mice increases the autonomous activity of calmodulin-dependent protein kinase II, which regulates atrial natriuretic factor gene expression. Mol Endocrinol 14 8 (2000) 1125-1136
68. Costa M.A., Elesgaray R., Caniffi C., Fellet A., and Arranz C. Role of cardiovascular nitric oxide system in C-type natriuretic peptide effects. Biochem Biophys Res Commun 359 1 (2007) 180-186
69. Costa G., Labadia A., Triguero D., Jimenez E., and Garcia-Pascual A. Nitrergic relaxation in urethral smooth muscle: involvement of potassium channels and alternative redox forms of NO. Naunyn-Schmied Arch Pharmacol 364 (2001) 516-523
70. Costa A.D.T., Pierre S.V., Cohen M.V., Downey J.M., and Garlid K.D. cGMP signalling in pre- and post-conditioning: the role of mitochondria. Cardiovasc Res 77 2 (2008) 344-352
71. D'Souza S.P., Yellon D.M., Martin C., Schulz R., Heusch G., Onody A., Ferdinandy P., and Baxter G.F. B-type natriuretic peptide limits infarct size in rat isolated hearts via K-ATP channel opening. Am J Physiol 284 5 (2003) H1592-H1600
72. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H., and LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 9311 (2002) 995-1003
73. Dai T., Tian Y., Tocchetti C.G., Katori T., Murphy A.M., Kass D.A., Paolocci N., and Gao W.D. Nitroxyl increases force development in rat cardiac muscle. J Physiol 580 Pt.3 (2007) 951-960
74. Das A., Xi L., and Kukreja R.C. Protein kinase g-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3 {beta}. J Biol Chem 283 43 (2008)
75. Date M.o., Morita T., Yamashita N., Nishida K., Yamaguchi O., Higuchi Y., Hirotani S., Matsumura Y., Hori M., Tada M., and Otsu K. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J Am Coll Cardiol 39 5 (2002) 907-912
76. de la Lande I.S., Siebert T.E., Bennett C.L., Stafford I., and Horowitz J.D. Influence of the endothelium on ex vivo tolerance and metabolism of glyceryl trinitrate in rat aorta. Eur J Pharmacol 486 (2004) 201-207
77. Delporte C., Winand J., Poloczek P., Von Geldern T., and Christophe J. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur J Pharmacol 224 2-3 (1992) 183-188
78. Denninger J.W., and Marletta M.A. Guanylate cyclase and the NO/cGMP signalling pathway. Biochim Biophys Acta 1411 (1999) 334-350
79. Derbyshire E.R., and Marletta M.A. Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol 191 (2009) 17-31
80. Deruelle P., Balasubramaniam V., Kunig A.M., Seedorf G.J., Markham N.E., and Abman S.H. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 90 2 (2006) 135-144
81. Devereux R.B., Dahlof B., Gerdts E., Boman K., Nieminen M.S., Papademetriou V., Rokkedal J., Harris K.E., Edelman J.M., and Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol - the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 11 (2004) 1456-1462
82. Dikalov S., Fink B., Skatchkov M., Stalleicken D., and Bassenge E. Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vivo and development of nitrate tolerance. J Pharmacol Exp Ther 286 2 (1998) 938-944
83. Dong D.L., Zhang Y., Lin D.H., Chen J., Patschan S., Goligorsky M.S., Nasjletti A., Yang B.F., and Wang W.H. Carbon monoxide stimulates the Ca2(+)-activated big conductance K channels in cultured human endothelial cells. Hypertension 50 (2007) 643-651
84. Dorn G.W. Containing hypertrophy with a PICOT fence. Circ Res 99 3 (2006) 228-230
85. Dorn G.W., and Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115 3 (2005) 527-537
86. Du Toit E.F., Meiring J., and Opie L.H. Relation of cyclic nucleotide ratios to ischemic and reperfusion injury in nitric oxide-donor treated rat hearts. J Cardiovasc Pharmacol 38 4 (2001) 529-538
87. Dubey R.K., Jackson E.K., and Luscher T.F. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell - role of cyclic nucleotides and angiotensin(1) receptors. J Clin Invest 96 1 (1995) 141-149
88. Dumitrascu R., Weissmann N., Ghofrani H.A., Dony E., Beuerlein K., Schmidt H., Stasch J.P., Gnoth M.J., Seeger W., Grimminger F., and Schermuly R.T. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 113 2 (2006) 286-295
89. Dunn F.G., McLenachan J., Isles C.G., Brown I., Dargie H.J., Lever A.F., Lorimer A.R., Murray G.D., Pringle S.D., and Robertson J.W. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. J Hypertens 8 8 (1990) 775-782
90. Ehmke H., Faulhaber J., Munter K., Kirchengast M., and Wiesner R.J. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. Hypertension 33 4 (1999) 954-960
91. Elkayam U. Nitrates in the treatment of congestive heart failure. Am J Cardiol 77 13 (1996) 41C-51C
92. Ellis A., Li C.G., and Rand M.J. Differential actions of L-cysteine on responses to nitric oxide, nitroxyl anions and EDRF in the rat aorta. Br J Pharmacol 129 (2000) 315-322
93. Ellmers L.J., Scott N.J.A., Piuhola J., Maeda N., Smithies O., Frampton C.M., Richards A.M., and Cameron V.A. Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 38 1-2 (2007) 245-257
94. Elrod J.W., Greer J.J.M., and Lefer D.J. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol 292 1 (2007) H342-H347
95. Esposito G., Prasad S.V., Rapacciuolo A., Mao L., Koch W.J., and Rockman H.A. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in in vivo pressure overload. Circulation 103 10 (2001) 1453-1458
96. Esposito G., Rapacciuolo A., Naga Prasad S.V., and Rockman H.A. Cardiac hypertrophy: role of G protein-coupled receptors. J Card Fail 8 6 Suppl (2002) S409-414
97. Evgenov O.V., Kohane D.S., Bloch K.D., Stasch J.P., Volpato G.P., Bellas E., Evgenov N.V., Buys E.S., Gnoth M.J., Graveline A.R., Liu R., Hess D.R., Langer R., and Zapol W.M. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 176 (2007) 1138-1145
98. Evgenov O.V., Pacher P., Schmidt P.M., Hasko G., Schmidt H., and Stasch J.P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5 9 (2006) 755-768
99. Favaloro J.L., and Kemp-Harper B.K. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res 73 3 (2007) 587-596
100. Favaloro J.L., and Kemp-Harper B.K. Redox variants of nitric oxide (NO{radical dot} and HNO) elicit vasorelaxation of resistance arteries via distinct mechanisms. Am J Physiol 296 5 (2009) H1274-H1280
101. Fayers K.E., Cummings M.H., Shaw K.M., and Laight D.W. Nitrate tolerance and the links with endothelial dysfunction and oxidative stress. Br J Clin Pharmacol 56 (2003) 620-628
102. Feelisch M., and Kelm M. Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochem Biophys Res Commun 180 1 (1991) 286-293
103. Fischer P., and Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 102 5 (2007) 393-411
104. Fischmeister R., Castro L., Abi-Gerges A., Rochais F., and Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol 142 2 (2005) 136-143
105. Fisher P.W., Salloum F., Das A., Hyder H., and Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111 13 (2005) 1601-1610
106. Fleischmann E.H., and Schmieder R.E. Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy?. Curr Cardiol Rep 4 6 (2002) 474-478
107. Folkerts G., Kloek J., Muijsers R.B., and Nijkamp F.P. Reactive nitrogen and oxygen species in airway inflammation. Eur J Pharmacol 429 1-3 (2001) 251-262
108. Foresti R., Bani-Hani M.G., and Motterlini R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med 34 4 (2008) 649-658
109. Foresti R., Hammad J., Clark J.E., Johnson T.R., Mann B.E., Friebe A., Green C.J., and Motterlini R. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br J Pharmacol 142 3 (2004) 453-460
110. Fraccarollo D., Widder J.D., Galuppo P., Thum T., Tsikas D., Hoffmann M., Ruetten H., Ertl G., and Bauersachs J. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118 8 (2008) 818-827
111. Fredj S., Bescond J., Louault C., and Potreau D. Interactions between cardiac cells enhance cardio-myocyte hypertrophy and increase fibroblast proliferation. J Cell Physiology 202 3 (2005) 891-899
112. Frey N., and Olson E.N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65 (2003) 45-79
113. Fujimoto H., Ohno M., Ayabe S., Kobayashi H., Ishizaka N., Kimura H., Yoshida K., and Nagai R. Carbon monoxide protects against cardiac ischemia-reperfusion injury in vivo via MAPK and Akt-eNOS pathways. Arterioscler Thromb Vasc Biol 24 10 (2004) 1848-1853
114. Fujisaki H., Ito H., Hirata Y., Tanaka M., Hata M., Lin M., Adachi S., Akimoto H., Marumo F., and Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 96 2 (1995) 1059-1065
115. Fukuto J.M., Chiang K., Hszieh R., Wong P.S.Y., and Chaudhurri G. The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium-derived relaxing factor. J Pharmacol Exp Ther 263 (1992) 546-551
116. Fukuto J.M., Hobbs A.J., and Ignarro L.J. Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems: the role of physiological oxidants and relevance to the biological activity of HNO. Biochem Biophys Res Commun 196 2 (1993) 707-713
117. Fukuto J.M., Wallace G.C., Hszieh R., and Chaudhuri G. Chemical oxidation of N-hydroxyguanidine compounds. Release of nitric oxide, nitroxyl and possible relationship to the mechanism of biological nitric oxide generation. Biochem Pharmacol 43 3 (1992) 607-613
118. Fulle H.J., and Garbers D.L. Guanylyl cyclases - a family of receptor-linked enzymes. Cell Biochem Funct 12 3 (1994) 157-165
119. Fuller S.J., Davies E.L., Gillespie-Brown J., Sun H., and Tonks N.K. Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes. Biochem J 323 Pt 2 (1997) 313-319
120. Furchgott R.F., and Jothianandan D. Endothelium-dependent and -independent vasodilation involving cyclic GMP: relaxation induced by nitric oxide, carbon monoxide and light. Blood vessels 28 (1991) 52-61
121. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 5789 (1980) 373-376
122. Furuya M., Yoshida M., Hayasi Y., Ohnuma N., Minamino N., Kangawa K., and Matsuo H. C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun 177 (1991) 927-931
123. Garreffa A.M., Woodman O.L., Cao A.H., and Ritchie R.H. Sodium nitroprusside protects adult rat cardiac myocytes from cellular injury induced by simulated ischemia: role for a non-cGMP-dependent mechanism of nitric oxide protection. J Cardiovasc Pharmacol 47 1 (2006) 1-8
124. Ghofrani H., Weimann G., Frey R., Voswinckel R., Thamm M., Bölkow D., Weissmann N., Mück W., Unger S., Wensing G., Schermuly R., and Grimminger F. BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension. BMC Pharmacology 7 (2007) S8
125. Gori T., and Parker J.D. Nitrate tolerance: a unifying hypothesis. Circulation 106 (2002) 2510-2513
126. Gori T., and Parker J.D. The puzzle of nitrate tolerance: pieces smaller that we thought?. Circulation 106 (2002) 2404-2408
127. Gray M.O., Long C.S., Kalinyak J.E., Li H.T., and Karliner J.S. Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 40 2 (1998) 352-363
128. Grider J.R. Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis. Am J Physiol 264 2 Pt 1 (1993) G334-340
129. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 6 (1994) 1141-1148
130. Guo Y., Stein A.B., Wu W.J., Tan W., Zhu X., Li Q.H., Dawn B., Motterlini R., and Bolli R. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. Am J Physiol 286 5 (2004) H1649-H1653
131. Gupta S., Das B., and Sen S. Cardiac hypertrophy: mechanisms and therapeutic opportunities. Antio Redox Signal 9 6 (2007) 623-652
132. Gupte S.A., Rupawalla T., Phillibert Jr. D., and Wolin M.S. NADPH and heme redox modulate pulmonary artery relaxation and guanylate cyclase activation by NO. Am J Physiol 277 6 Pt 1 (1999) L1124-L1132
133. Gustafsson A.B., and Gottlieb R.A. Autophagy in ischemic heart disease. Circ Res 104 2 (2009) 150-158
134. Haider A.W., Larson M.G., Benjamin E.J., and Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32 5 (1998) 1454-1459
135. Hamad A.M., Johnson S.R., and Knox A.J. Antiproliferative effects of NO and ANP in cultured human airway smooth muscle. Am J Physiol 277 5 Pt 1 (1999) L910-918
136. Han J., Kim N., Kim E., Ho W.K., and Earm Y.E. Modulation of ATP-sensitive potassium channels by cGMP-dependent protein kinase in rabbit ventricular myocytes. J Biol Chem 276 25 (2001) 22140-22147
137. Haneda M., Araki S., Sugimoto T., Togawa M., Koya D., and Kikkawa R. Differential inhibition of mesangial MAP kinase cascade by cyclic nucleotides. Kidney Int 50 2 (1996) 384-391
138. Hannan R.D., Jenkins A., Jenkins A.K., and Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol 30 8 (2003) 517-527
139. Hannken T., Schroeder R., Stahl R.A., and Wolf G. Atrial natriuretic peptide attenuates ANG II-induced hypertrophy of renal tubular cells. Am J Physiol 281 1 (2001) F81-90
140. Haq S., Choukroun G., Kang Z.B., Ranu H., Matsui T., Rosenzweig A., Molkentin J.D., Alessandrini A., Woodgett J., Hajjar R., Michael A., and Force T. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151 1 (2000) 117-130
141. Hardt S.E., and Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res 63 3 (2004) 500-509
142. Harris I.S., Zhang S., Treskov I., Kovacs A., Weinheimer C., and Muslin A.J. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110 6 (2004) 718-723
143. Hayashi M., Tsutamoto T., Wada A., Maeda K., Mabuchi N., Tsutsui T., Horie H., Ohnishi M., and Kinoshita M. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37 7 (2001) 1820-1826
144. Heller R., Polack T., Grabner R., and Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 144 1 (1999) 49-57
145. Hink U., Oelze M., Kolb P., Bachschmid M., Zou M.H., Daiber A., Mollnau H., August M., Baldus S., Tsilimingas N., Walter U., Ullrich V., and Munzel T. Role of peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 42 10 (2003) 1826-1834
146. Ho Y., Samarasinghe R., Knoch M.E., Lewis M., Aizenman E., and DeFranco D.B. Selective inhibition of mitogen-activated protein kinase phosphatases by zinc accounts for extracellular signal-regulated kinase 1/2-dependent oxidative neuronal cell death. Mol Pharmacol 74 4 (2008) 1141-1151
147. Hobbs A.J. Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 18 12 (1997) 484-491
148. Hobbs A.J. Soluble guanylate cyclase. Expert Opin Ther Targets 4 6 (2000) 735-749
149. Hobbs A.J., Fukuto J.M., and Ignarro L.J. Formation of free nitric oxide from l-arginine by nitric oxide synthase: direct enhancement of generation by superoxide dismutase. Proc Natl Acad Sci USA 91 23 (1994) 10992-10996
150. Hofmann F., Ammendola A., and Schlossmann J. Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113 10 (2000) 1671-1676
151. Holmes A.S., Chirkov Y.Y., Willoughby S.R., Poropat S., Pereira J., and Horowitz J.D. Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance. Br J Clin Pharmacol 60 4 (2005) 355-363
152. Holtwick R., van Eickels M., Skryabin B.V., Baba H.A., Bubikat A., Begrow F., Schneider M.D., Garbers D.L., and Kuhn M. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 9 (2003) 1399-1407
153. 2+ channel as a potential mediator of pathology during alterations in cellular redox state. Heart Lung Circ 18 1 (2009) 3-10
154. Horiba M., Muto T., Ueda N., Opthof T., Miwa K., Hojo M., Lee J.K., Kamiya K., Kodama I., and Yasui K. T-type Ca2+ channel blockers prevent cardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers. Life Sci 82 11-12 (2008) 554-560
155. Horio T., Nishikimi T., Yoshihara F., Matsuo H., Takishita S., and
156. Horowitz J.D., Antman E.M., Lorell B.H., Barry W.H., and Smith T.W. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 68 6 (1983) 1247-1253
157. Horowitz J.D., Henry C.A., Syrjanen M.L., Louis W.J., Fish R.D., Smith T.W., and Antman E.M. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina-pectoris. Circulation 77 4 (1988) 787-794
158. Iachini Bellisarii F., Gallina S., Zimarino M., and De Caterina R. Mechanisms of nitrate tolerance: potential roles of folate. Eur J Clin Invest 33 11 (2003) 933-940
159. Ikeda K., Tojo K., Udagawa T., Otsubo C., Ishikawa M., Tokudome G., Hosoya T., Tajima N., Nakao K., and Kawamura M. Cellular physiology of rat cardiac myocytes in cardiac fibrosis: in vitro simulation using the cardiac myocyte/cardiac non-myocyte co-culture system. Hypertens Res 31 4 (2008) 693-706
160. Ingi T., Cheng J., and Ronnett G.V. Carbon monoxide: an endogenous modulator of the nitric oxide-cyclic GMP signaling system. Neuron 16 (1996) 835-842
161. Irvine J.C., Favaloro J.L., and Kemp-Harper B.K. NO- activates soluble guanylate cyclase and K-v channels to vasodilate resistance arteries. Hypertension 41 6 (2003) 1301-1307
162. Irvine J.C., Favaloro J.L., Widdop R.E., and Kemp-Harper B.K. Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae. Hypertension 49 4 (2007) 885-892
163. Irvine J.C., Ritchie R.H., Favaloro J.L., Andrews K.L., Widdop R.E., and Kemp-Harper B.K. Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci 29 12 (2008) 601-608
164. Ito H., Bell D., Tamamori M., Nozato T., Shimojo T., Adachi S., Abe S., Marumo F., and Hiroe M. Calcitonin gene-related peptide (CGRP) and hypertrophy of cardiomyocytes. Heart Vessels (1997) 15-17
165. Izumo S., Lompre A.M., Matsuoka R., Koren G., Schwartz K., Nadal-Ginard B., and Mahdavi V. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest 79 3 (1987) 970-977
166. Jackson E.B., Mukhopadhyay S., and Tulis D.A. Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside. Curr Vasc Pharmacol 5 1 (2007) 1-14
167. Jones L.G., Rozich J.D., Tsutsui H., and Cooper G.t. Endothelin stimulates multiple responses in isolated adult ventricular cardiac myocytes. Am J Physiol 263 5 Pt 2 (1992) H1447-1454
168. Jugdutt B.I., and Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications - effect of timing, dosage, and infarct location. Circulation 78 4 (1988) 906-919
169. Kaczorowski D.J., and Zuckerbraun B.S. Carbon monoxide: medicinal chemistry and biological effects. Curr Med Chem 14 (2007) 2720-2725
170. Kaddoura S., Firth J.D., Boheler K.R., Sugden P.H., and Poole-Wilson P.A. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation 93 11 (1996) 2068-2079
171. Kakishita M., Nakamura K., Asanuma M., Morita H., Saito H., Kusano K., Nakamura Y., Emori T., Matsubara H., Sugaya T., Ogawa N., and Ohe T. Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol 42 Suppl 1 (2003) S67-70
172. Kalk P., Godes M., Relle K., Rothkegel C., Hucke A., Stasch J.P., and Hocher B. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 148 6 (2006) 853-859
173. Kaneko K., Susic D., Nunez E., and Frohlich E.D. Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat. J Hypertens 14 5 (1996) 645-653
174. Kapiloff M.S. Contributions of protein kinase A anchoring proteins to compartmentation of cAMP signaling in the heart. Mol. Pharmacol. 62 2 (2002) 193-199
175. 2+-ATPase of cardiac sarcoplasmic reticulum. Mol Cell Biochem 248 (2003) 41-47
176. Kasama S., Furuya M., Toyama T., Ichikawa S., and Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 29 12 (2008) 1485-1494
177. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., Ichikawa S., Suzuki T., and Kurabayashi M. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 49 6 (2007) 667-674
178. Katori T., Donzelli S., Tocchetti C.G., Miranda K.M., Cormaci G., Thomas D.D., Ketner E.A., Lee M.J., Maneardi D., Wink D.A., Kass D.A., and Paolocci N. Peroxynitrite and myocardial contractility: in vivo versus in vitro effects. Free Rad Biol Med 41 10 (2006) 1606-1618
179. Katori T., Hoover D.B., Ardell J.L., Helm R.H., Belardi D.F., Tocchetti C.G., Forfia P.R., Kass D.A., and Paolocci N. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ Res 96 2 (2005) 234-243
180. Kawada H., Niwano S., Niwano H., Yumoto Y., Wakisaka Y., Yuge M., Kawahara K., and Izumi T. Tumor necrosis factor-alpha downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyocytes - a possible cause of electrical remodeling in diseased hearts. Circ J 70 5 (2006) 605-609
181. Keith R.A., Burkman A.M., Sokoloski T.D., and Fertel R.H. Vascular tolerance to nitroglycerin and cyclic GMP generation in rat aortic smooth muscle. J Pharmacol Exp Ther 221 3 (1982) 525-531
182. Kemp-Harper B., and Schmidt H. cGMP in the vasculature. Handb Exp Pharmacol 191 (2009) 447-467
183. Kempf T., and Wollert K.C. Nitric oxide and the enigma of cardiac hypertrophy. Bioessays 26 6 (2004) 608-615
184. Kerkela R., Pikkarainen S., Majalahti-Palviainen T., Tokola H., and Ruskoaho H. Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcription factor-mediated regulation of B-type natriuretic peptide gene. J Biol Chem 277 16 (2002) 13752-13760
185. Kishimoto I., Rossi K., and Garbers D.L. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A 98 5 (2001) 2703-2706
186. Klein M., Schermuly R.T., Ellinghaus P., Milting H., Riedl B., Nikolova S., Pullamsetti S.S., Weissmann N., Dony E., Savai R., Ghofrani H.A., Grimminger F., Busch A.E., and Schafer S. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118 20 (2008) 2081-2090
187. Klinger J.R., Warburton R.R., Pietras L.A., Smithies O., Swift R., and Hill N.S. Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am J Physiol 276 5 (1999) L868-L874
188. Knorr A., Hirth-Dietrich C., Alonso-Alija C., Harter M., Hahn M., Keim Y., Wunder F., and Stasch J.P. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58 2 (2008) 71-80
189. Koller K.J., and Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation 86 4 (1992) 1081-1088
190. Komuro I. Molecular mechanism of cardiac hypertrophy and development. Jpn Circ J 65 5 (2001) 353-358
191. Kraus-Friedmann N. Cyclic nucleotide-gated channels in non-sensory organs. Cell Calcium 27 3 (2000) 127-138
192. Krauser D.G., and Devereux R.B. Ventricular hypertrophy and hypertension - prognostic elements and implications for management. Herz 31 4 (2006) 305-316
193. Kuga H., Ogawa K., Oida A., Taguchi I., Nakatsugawa M., Hoshi T., Sugimura H., Abe S., and Kaneko N. Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction. Circ J 67 5 (2003) 443-448
194. Kukreja R.C., Ockaili R., Salloum F., Yin C., Hawkins J., Das A., and Xi L. Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol 36 2 (2004) 165-173
195. Kumar R., Namiki T., and Joyner R.W. Effects of cGMP on L-type calcium current of adult and newborn rabbit ventricular cells. Cardiovasc Res 33 3 (1997) 573-582
196. Kuno A., Solenkova N.V., Solodushko V., Dost T., Liu Y., Yang X.M., Cohen M.V., and Downey J.M. Infarct limitation by a protein kinase G activator at reperfusion in rabbit hearts is dependent on sensitizing the heart to A2b agonists by protein kinase C. Am J Physiol 295 3 (2008)
197. Laks M.M., Morady F., and Swan H.J. Myocardial hypertrophy produced by chronic infusion of subhypertensive doses of norepinephrine in the dog. Chest 64 1 (1973) 75-78
198. Lammerding J., Kamm R.D., and Lee R.T. Mechanotransduction in cardiac myocytes. Ann N Y Acad Sci 1015 (2004) 53-70
199. Langenickel T.H., Buttgereit J., Pagel-Langenickel I., Lindner M., Monti J., Beuerlein K., Al-Saadi N., Plehm R., Popova E., Tank J., Dietz R., Willenbrock R., and Bader M. Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci U S A 103 12 (2006) 4735-4740
200. Lapp H., Mitrovic V., Franz N., Heuer H., Buerke M.J., Mück W., Unger S., Wensing G., and Frey R. BAY 58-2667, a soluble guanylate cycasle activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile. BMC Pharmacology 7 (2007) S9
201. Laser M., Willey C.D., Jiang W., Cooper G.t., Menick D.R., Zile M.R., and Kuppuswamy D. Integrin activation and focal complex formation in cardiac hypertrophy. J Biol Chem 275 45 (2000) 35624-35630
202. Laskowski A., Woodman O.L., Cao A.H., Drummond G.R., Marshall T., Kaye D.M., and Ritchie R.H. Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72 1 (2006) 112-123
203. Laursen J.B., Boesgaard S., Poulsen H.E., and Aldershvile J. Nitrate tolerance impairs nitric oxide-mediated vasodilation in vivo. Cardiovasc Res 31 (1996) 814-819
204. Lee W.I., and Fung H.L. Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. Nitric Oxide 8 2 (2003) 103-110
205. Lefer D.J., Nakanishi K., Johnston W.E., and Vinten-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric-oxide donor after acute myocardial-ischemia and reperfusion in dogs. Circulation 88 5 (1993) 2337-2350
206. Levin E.R., and Frank H.J. Natriuretic peptides inhibit rat astroglial proliferation: mediation by C receptor. Am J Physiol 261 2 Pt 2 (1991) R453-457
207. Levy D., Anderson K.M., Savage D.D., Kannel W.B., Christiansen J.C., and Castelli W.P. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108 1 (1988) 7-13
208. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 22 (1990) 1561-1566
209. Li C.G., Karagiannis J., and Rand M.J. Comparison of the redox forms of nitrogen monoxide with the nitrergic transmitter in the rat anococcygeus muscle. Br J Pharmacol 127 4 (1999) 826-834
210. Liang Q., De Windt L.J., Witt S.A., Kimball T.R., Markham B.E., and Molkentin J.D. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 276 32 (2001) 30245-30253
211. Lin K.F., Chao J., and Chao L. Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in salt-sensitive rats. Hum Gene Ther 9 10 (1998) 1429-1438
212. Lin C.S., Lin G.T., Xin Z.C., and Lue T.F. Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Design 12 27 (2006) 3439-3457
213. Linz W., Scholkens B.A., and Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 11 7 (1989) 1325-1350
214. Liu J.C., Chan P., Chen J.J., Lee H.M., Lee W.S., Shih N.L., Chen Y.L., Hong H.J., and Cheng T.H. The inhibitory effect of trilinolein on norepinephrine-induced beta-myosin heavy chain promoter activity, reactive oxygen species generation, and extracellular signal-regulated kinase phosphorylation in neonatal rat cardiomyocytes. J Biomed Sci 11 1 (2004)
215. Lopez B.E., Rodriguez C.E., Pribadi M., Cook N.M., Shinyashiki M., and Fukuto J.M. Inhibition of yeast glycolysis by nitroxyl (HNO): mechanism of HNO toxicity and implications to HNO biology. Arch Biochem Biophyss 442 1 (2005) 140-148
216. Loscalzo J. N-acetylcysteine potentiates inhibition of platelet-aggregation by nitroglycerin. J. Clin. Invest 76 2 (1985) 703-708
217. Loyer X., Gomez A.M., Milliez P., Fernandez-Velasco M., Vangheluwe P., Vinet L., Charue D., Vaudin E., Zhang W., Sainte-Marie Y., Robidel E., Marty I., Mayer B., Jaisser F., Mercadier J.J., Richard S., Shah A.M., Benitah J.P., Samuel J.L., and Heymes C. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation 117 25 (2008) 3187-3198
218. Luyken J., Hannan R.D., Cheung J.Y., and Rothblum L.I. Regulation of rDNA transcription during endothelin-1-induced hypertrophy of neonatal cardiomyocytes. Hyperphosphorylation of upstream binding factor, an rDNA transcription factor. Circ Res 78 3 (1996) 354-361
219. Ma X.L., Gao F., Liu G.L., Lopez B.L., Christopher T.A., Fukuto J.M., Wink D.A., and Feelisch M. Opposite effects of nitric oxide and nitroxyl on postischemic myocardial injury. Proc Natl Acad Sci U S A 96 25 (1999) 14617-14622
220. Macfarland R.T. Molecular aspects of cyclic-GMP signaling. Zoo Sci 12 2 (1995) 151-163
221. MacPherson J.D., Gillespie T.D., Dunkerley H.A., Maurice D.H., and Bennett B.M. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation. J Pharmacol Exp Ther 317 1 (2006) 188-195
222. Maeda Y., Ikeda U., Oya K., Shimpo M., Ueno S., Okada K., Saito T., Mano H., Ozawa K., and Shimada K. Endogenously generated nitric oxide by nitric-oxide synthase gene transfer inhibits cellular proliferation. J Pharmacol Exp Ther 292 1 (2000) 387-393
223. Mahmarian J.J., Moye L.A., Chinoy D.A., Sequeira R.F., Habib G.B., Henry W.J., Jain A., Chaitman B.R., Weng C.S.W., Morales-Ballejo H., and Pratt C.M. Transdermal nitroglycerin patch therapy improves left ventricular function and prevents remodeling after acute myocardial infarction - results of a multicenter prospective randomized, double-blind, placebo-controlled trial. Circulation 97 20 (1998) 2017-2024
224. Mancia G., and Zanchetti A. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J. Hypertens 26 2 (2008) 164-168
225. Mangione N.J., and Glasser S.P. Phenomenon of nitrate tolerance. Am Heart J 128 1 (1994) 137-146
226. Marin J., and Rodriguez-Martinez M.A. Role of vascular nitric oxide in physiological and pathological conditions. Pharmacol Ther 75 2 (1997) 111-134
227. Masciotra S., Picard S., and Deschepper C.F. Cosegregation analysis in genetic crosses suggests a protective role for atrial natriuretic factor against ventricular hypertrophy. Circ Res 84 12 (1999) 1453-1458
228. Masini E., Vannacci A., Marzocca C., Pierpaoli S., Giannini L., Fantappié O., Mazzanti R., and Mannaioni P.F. Heme oxygenase-1 and the ischemia-reperfusion injury in the rat heart. Exp Biol Med 228 (2003) 546-549
229. Massoudy P., Becker B.F., and Gerlach E. Nitric oxide accounts for postischemic cardioprotection resulting from angiotensin-converting enzyme inhibition: indirect evidence for a radical scavenger effect in isolated guinea pig heart. J Cardiovasc Pharmacol 25 3 (1995) 440-447
230. Masuyama H., Tsuruda T., Kato J., Imamura T., Asada Y., Stasch J.P., Kitamura K., and Eto T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 48 5 (2006) 972-978
231. McDonald K.M., Francis G.S., Matthews J., Hunter D., and Cohn J.N. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. J Am Coll Cardiol 21 2 (1993) 514-522
232. McKinsey T.A., and Kass D.A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov 6 8 (2007) 617-635
233. McMullen J.R., and Jennings G.L. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 34 4 (2007) 255-262
234. Meijs M.F.L., de Windt L.J., de Jonge N., Cramer M.J.M., Bots M.L., Mali W., and Doevendans P.A. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 14 2 (2007) 157-171
235. Michaels A.D., Chatterjee K., and De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Cardiac Fail 11 (2005) 425-431
236. Mihm M.J., Coyle C.M., Jing L., and Bauer J.A. Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther 291 1 (1999) 194-198
237. Miller W.L., Burnett J.C., Hartman K.A., Henle M.P., Burritt M.F., and Jaffe A.S. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 51 (2005) 569-577
238. Miller, T.W., Cherney, M.M., Lee, A.L., Francoleon, N.E., Farmer, P.J., King, S.B., Hobbs, A.J., Miranda, K.M., Burstyn, J.N., Fukuto, J.M. (2009). The Effects of Nitroxyl (HNO) on Soluble Guanylate Cyclase Activity: interactions at ferrous heme and cysteine thiols. J Biol Chem 284, 21788-21796.
239. Minamiyama Y., Imaoka S., Takemura S., Okada S., Inque M., and Funae Y. Escape from tolerance of organic nitrate by induction of cytochrome P450. Free Rad Biol Med 31 11 (2001) 1498-1508
240. Miranda K.M., Katori T., Torres de Holding C.L., Thomas L., Ridnour L.A., McLendon W.J., Cologna S.M., Dutton A.S., Champion H.C., Mancardi D., Tocchetti C.G., Saavedra J.E., Keefer L.K., Houk K.N., Fukuto J.M., Kass D.A., Paolocci N., and Wink D.A. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in vivo. J Med Chem 48 26 (2005) 8220-8228
241. Miranda K.M., Nims R.W., Thomas D.D., Espey M.G., Citrin D., Bartberger M.D., Paolocci N., Fukuto J.M., Feelisch M., and Wink D.A. Comparison of the reactivity of nitric oxide and nitroxyl with heme proteins. A chemical discussion of the differential biological effects of these redox related products of NOS. J Inorganic Biochem 93 1-2 (2003) 52-60
242. Miranda K.M., Paolocci N., Katori T., Thomas D.D., Ford E., Bartberger M.D., Espey M.G., Kass D.A., Feelisch M., Fukuto J.M., and Wink D.A. A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system. Proc Natl Acad Sci USA 100 16 (2003) 9196-9201
243. Miranda K.M., Yamada K., Espey M.G., Thomas D.D., DeGraff W.G., Mitchell J.B., Krishna M.C., Colton C.A., and Wink D.A. Further evidence for distinct reactive intermediates from nitroxyl and peroxynitrite: effects of buffer composition on the chemistry of Angeli's salt and synthetic peroxynitrite. Arch Biochem Biophys 401 (2002) 134-144
244. Mito S., Ozono R., Oshima T., Yano Y., Watari Y., Yamamoto Y., Brydun A., Igarashi K., and Yoshizumi M. Myocardial protection against pressure overload in mice lacking Bach1, a transcriptional repressor of heme oxygenase-1. Hypertension 51 6 (2008) 1570-1577
245. Moazemi K., Chana J.S., Willard A.M., and Kocheril A.G. Intravenous vasodilator therapy on congestive heart failure. Drugs Aging 20 7 (2003) 485-508
246. Molkentin J.D., and Dorn I.G. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001) 391-426
247. Mollnau H., Wenzel P., Oelze M., Treiber N., Pautz A., Schulz E., Schuhmacher S., Reifenberg K., Stalleicken D., Scharffetter-Kochanek K., Kleinert H., Munzel T., and Daiber A. Mitochondrial oxidative stress and nitrate tolerance-comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD+/- mice. BMC Cardiovasc Dis 6 (2006) 44
248. Moncada S., and Higgs E.A. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147 (2006) S193-S201
249. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 2 (1991) 109-142
250. Morisco C., Seta K., Hardt S.E., Lee Y., Vatner S.F., and Sadoshima J. Glycogen synthase kinase 3beta regulates GATA4 in cardiac myocytes. J Biol Chem 276 30 (2001) 28586-28597
251. Motterlini R., Clark J.E., Foresti R., Sarathchandra P., Mann B.E., and Green C.J. Carbon monoxide-releasing molecules - characterization of biochemical and vascular activities. Circ Res 90 2 (2002) E17-E24
252. Munzel T., Daiber A., Ullrich V., and Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase. Arterio Thromb Vasc Biol 25 8 (2005) 1551-1557
253. Munzel T., and Harrison D.G. Evidence for a role of oxygen-derived free radicals and protein kinase C in nitrate tolerance. J Mol Med 75 (1997) 891-900
254. Munzel T., Li H., Mollnau H., Hink U., Matheis E., Hartmann M., Oelze M., Skatchkov M., Warnholtz A., Duncker L., Meinertz T., and Forstermann U. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res 86 (2000) e7-e12
255. Musameh M.D., Fuller B.J., Mann B.E., Green C.J., and Motterlini R. Positive inotropic effects of carbon monoxide-releasing molecules (CO-RMs) in the isolated perfused rat heart. Br J Pharmacol 149 8 (2006) 1104-1112
256. Muslin A.J. MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115 7 (2008) 203-218
257. Nadal-Ginard B., Kajstura J., Leri A., and Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 92 2 (2003) 139-150
258. Nagatomo Y., Carabello B.A., Hamawaki M., Nemoto S., Matsuo T., and McDermott P.J. Translational mechanisms accelerate the rate of protein synthesis during canine pressure-overload hypertrophy. Am J Physiol 277 6 Pt 2 (1999) H2176-2184
259. Nagayama T., Hsu S., Zhang M.L., Koitabashi N., Bedja D., Gabrielson K.L., Takimoto E., and Kass D.A. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53 2 (2009) 207-215
260. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98 8 (1998) 794-799
261. Nakamura T.Y., Iwata Y., Arai Y., Komamura K., and Wakabayashi S. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103 8 (2008) 891-U293
262. Nakamura F., Nagano M., Higaki J., Higashimori K., Morishita R., Mikami H., and Ogihara T. The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats. Clin Exp Pharmacol Physiol 20 3 (1993) 135-140
263. Nakanishi M., Saito Y., Kishimoto I., Harada M., Kuwahara K., Takahashi N., Kawakami R., Nakagawa Y., Tanimoto K., Yasuno S., Usami S., Li Y.H., Adachi Y., Fukamizu A., Garbers D.L., and Nakao K. Role of natriuretic peptide receptor guanylyl cyclase-A in myocardial infarction evaluated using genetically engineered mice. Hypertension 46 2 (2005) 441-447
264. Nakao K., Ogawa Y., Suga S., and Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens 10 9 (1992) 907-912
265. Nazario B., Hu R.M., Pedram A., Prins B., and Levin E.R. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest 95 3 (1995) 1151-1157
266. Needleman P., and Johnson E. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 184 3 (1973) 709-715
267. Nguyen A., Chen P., and Cai H. Role of CaMKII in hydrogen peroxide activation of ERK1/2, p38 MAPK, HSP27 and actin reorganization in endothelial cells. FEBS Lett 572 1-3 (2004) 307-313
268. Nishikimi T., Maeda N., and Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69 2 (2006) 318-328
269. Nunez D.J., Dickson M.C., and Brown M.J. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest 90 5 (1992) 1966-1971
270. Oliver P.M., Fox J.E., Kim R., Rockman H.A., Kim H.S., Reddick R.L., Pandey K.N., Milgram S.L., Smithies O., and Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA 94 26 (1997) 14730-14735
271. Olivetti G., Cigola E., Maestri R., Lagrasta C., Corradi D., and Quaini F. Recent advances in cardiac hypertrophy. Cardiovasc Res 45 1 (2000) 68-75
272. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ Res 100 3 (2007) 309-327
273. Pagel-Langenickel I., Buttgereit J., Bader M., and Langenickel T.H. Natriuretic peptide receptor B signaling in the cardiovascular system: protection from cardiac hypertrophy. J Mol Med 85 8 (2007) 797-810
274. Pagliaro P., Mancardi D., Rastaldo R., Penna C., Gattullo D., Miranda K.M., Feelisch M., Wink D.A., Kass D.A., and Paolocci N. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Rad Biol Med 34 1 (2003) 33-43
275. Pal B., and Kitagawa T. Interactions of soluble guanylate cyclase with diatomics as probed by resonance Raman spectroscopy. J Inorg Biochem 99 1 (2005) 267-279
276. Paolocci N., Ekelund U.E.G., Isoda T., Ozaki M., Vandegaer K., Georgakopoulos D., Harrison R.W., Kass D.A., and Hare J.M. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol 279 4 (2000) H1982-H1988
277. Paolocci N., Jackson M.I., Lopez B.E., Miranda K., Tocchetti C.G., Wink D.A., Hobbs A.J., and Fukuto J.M. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the janus face of NO. Pharmacol Ther 113 2 (2007) 442-458
278. Paolocci N., Katori T., Champion H.C., St John M.E., Miranda K.M., Fukuto J.M., Wink D.A., and Kass D.A. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence from beta-adrenergic signaling. Proc Natl Acad Sci USA 100 9 (2003) 5537-5542
279. Paolocci N., Saavedra W.F., Miranda K.M., Martignani C., Isoda T., Hare J.M., Espey M.G., Fukuto J.M., Feelisch M., Wink D.A., and Kass D.A. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci USA 98 18 (2001) 10463-10468
280. Parker J.D., and Parker J.O. Nitrate therapy for stable angina pectoris. New Engl J Med 338 8 (1998) 520-531
281. Passier R., Zeng H., Frey N., Naya F.J., Nicol R.L., McKinsey T.A., Overbeek P., Richardson J.A., Grant S.R., and Olson E.N. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 105 10 (2000) 1395-1406
282. Patel J.B., Valencik M.L., Pritchett A.M., Burnett J.C., McDonald J.A., and Redfield M.M. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol 289 2 (2005) H777-H784
283. Paulis L., Matuskova J., Adamcova M., Pelouch V., Simko J., Krajcirovicova K., Potacova A., Hulin I., Janega P., Pechanova O., and Simko F. Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of l-arginine and spironolactone. Acta Physiol (Oxf) 194 1 (2008) 45-55
284. Peacock W.P., Emerman C.L., Silver M.A., and on behalf of the PROACTION Study Group. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 23 (2005) 327-331
285. Pedram A., Razandi M., Hu R.M., and Levin E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 272 27 (1997) 17097-17103
286. Perez N.G., Piaggio M.R., Ennis I.L., Garciarena C.D., Morales C., Escudero E.M., Cingolani O.H., de Cingolani G.C., Yang X.P., and Cingolani H.E. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 49 5 (2007) 1095-1103
287. Pilz R.B., and Casteel D.E. Regulation of gene expression by cyclic GMP. Circ Res 93 11 (2003) 1034-1046
288. Pimentel D.R., Amin J.K., Xiao L., Miller T., Viereck J., Oliver-Krasinski J., Baliga R., Wang J., Siwik D.A., Singh K., Pagano P., Colucci W.S., and Sawyer D.B. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ Res 89 5 (2001) 453-460
289. -) using l-cysteine. Biochem Biophys Res Comm 201 1 (1994) 54-62
290. Planavila A., Rodriguez-Calvo R., Palomer X., Coll T., Sanchez R.M., Merlos M., Laguna J.C., and Vazquez-Carrera M. Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli. Biochim Biophys Acta 1781 1-2 (2008) 26-35
291. Pokreisz P., Vandenwijngaert S., Bito V., Van den Bergh A., Lenaerts I., Busch C., Marsboom G., Gheysens O., Vermeersch P., Biesmans L., Liu X.S., Gillijns H., Pellens M., Van Lommel A., Buys E., Schoonjans L., Vanhaecke J., Verbeken E., Sipido K., Herijgers P., Bloch K.D., and Janssens S.P. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119 3 (2009) 408-U493
292. Prins B.A., Weber M.J., Hu R.M., Pedram A., Daniels M., and Levin E.R. Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor. Potential role in the inhibition of astrocyte proliferation. J Biol Chem 271 24 (1996) 14156-14162
293. Prisant L.M. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 121 8 (2008) S8-S15
294. Pyriochou A., and Papapetropoulos A. Soluble guanylyl cyclase: more secrets revealed. Cell Signal 17 4 (2005) 407-413
295. Rajendran S., Willoughby S., Chan W., Liberts E., Heresztyn T., Saha M., Marber M., Norman R., and Horowitz J. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 204 2 (2009) 509-514
296. Rapoport R.M., Waldman S., Ginsburg R., Molina C.R., and Murad F. Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. J Cardiovasc Pharmacol 10 1 (1987) 82-89
297. Ratz J.D., Fraser A.B., Rees-Milton K.J., Adams M.A., and Bennett B.M. Endothelin receptor antagonism does not prevent the development of in vivo glyceryl trinitrite tolerance in the rat. J Pharmacol Exp Ther 295 2 (2000) 578-585
298. Ritchie R.H. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 18 11 (2009) 11-18
299. Ritchie R.H., and Delbridge L.M.D. Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect?. Clin Exp Pharmacol Physiol 33 1-2 (2006) 171-178
300. Ritchie R.H., Cao A.H., Kiriazis H., Xu Q., Du X.J., and Kaye D.M. Atrial natriuretic peptide (ANP) prevents diabetic cardiomyopathy via suppression of NADPH oxidase (abstract). Circulation 114 18 (2006) 132-132
301. Ritchie R.H., Gossain S., Irvine J.C., Kaye D.M., and Kemp-Harper B.K. Isopropylamine NONOate (IPA/NO) prevents cardiomyocyte hypertrophy via nitroxyl (HNO)/cGMP-dependent signalling (abstract). Heart Lung Circ 17 (2008) S230
302. Ritchie R.H., Lin E.Q., Cao A.H., Patel R., Kaye D.M., and Kemp-Harper B.K. The NO redox sibling, nitroxyl (HNO), blocks cardiomyocyte hypertrophy via suppression of NADPH oxidase (abstract). Circulation 116 16 Suppl II (2007) 19-II_20
303. Ritchie R.H., Marsh J.D., Lancaster W.D., Diglio C.A., and Schiebinger R.J. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 31 1 (1998) 39-44
304. Ritchie R.H., Marsh J.D., and Schiebinger R.J. Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70(S6K). Am J Physiol 276 4 Pt 2 (1999) H1393-1398
305. Ritchie R.H., Quinn J.M., Cao A.H., Drummond G.R., Kaye D.M., Favaloro J.M., Proietto J., and Delbridge L.M.D. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 42 6 (2007) 1119-1128
306. Ritchie R.H., Rosenkranz A.C., Huynh L.P., Stephenson T., Kaye D.M., and Dusting G.J. Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signaling. Am J Physiol 287 3 (2004) H1179-1185
307. Ritchie, R. H., Rosenkranz, A. C., Kaye, D. M., 2009. B-Type natriuretic peptide: Endogenous tegulator of myocardial structure. Biomarker and therapeutic target. Curr Mol Med 9(7), 814-825.
308. Ritchie R.H., Schiebinger R.J., LaPointe M.C., and Marsh J.D. Angiotensin II-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide. Am J Physiol 275 4 Pt 2 (1998) H1370-H1374
309. Roenicke V., Leclair S., Hoffmann A., Becker M., Szado T., Kirsch T., Stoss O., Nave B.T., and Henkel T. Emerging therapeutic targets in chronic heart failure: part I. Expert Opin Ther Targets 6 6 (2002) 649-658
310. Rosei E.A., and Muiesan M.L. Early target organ damage and its reversibility: the heart. Clin Exp Hypertens 26 7-8 (2004) 673-687
311. Rosenfeld C.R., White R.E., Roy T., and Cox B.E. Calcium-activated potassium channels and nitric oxide coregulate estrogen-induced vasodilation. Am J Physiol 279 1 (2000) H319-H328
312. Rosenkranz A.C., Dusting G.J., and Ritchie R.H. Endothelial dysfunction limits the antihypertrophic action of bradykinin in rat cardiomyocytes. J Mol Cell Cardiol 32 6 (2000) 1119-1126
313. Rosenkranz A.C., Hood S.G., Woods R.L., Dusting G.J., and Ritchie R.H. Acute antihypertrophic actions of bradykinin in the rat heart - importance of cyclic GMP. Hypertension 40 4 (2002) 498-503
314. Rosenkranz A.C., Hood S.G., Woods R.L., Dusting G.J., and Ritchie R.H. B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP. Diabetes 52 9 (2003)
315. Rosenkranz A.C., Woods R.L., Dusting G.J., and Ritchie R.H. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res 57 2 (2003) 515-522
316. Rothermel B.A., McKinsey T.A., Vega R.B., Nicol R.L., Mammen P., Yang J., Antos C.L., Shelton J.M., Bassel-Duby R., Olson E.N., and Williams R.S. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98 6 (2001) 3328-3333
317. Rudolph A., Abdel-Aty H., Bohl S., Boye P., Zagrosek A., Dietz R., and Schultz-Menger J. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 53 3 (2009) 284-291
318. Ruggenenti P., Iliev I., Costa G.M., Parvanova A., Perna A., Giuliano G.A., Motterlini N., Ene-Iordache B., Remuzzi G., and Benedict Study Group. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 31 8 (2008) 1629-1634
319. Sabri A., Hughie H.H., and Lucchesi P.A. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antiox Redox Signal 5 6 (2003) 731-740
320. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
321. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59 (1997) 551-571
322. Sage P.R., de la Lande I.S., Stafford I., Bennett C.L., Phillipov G., Stubberfield J., and Horowitz J.D. Nitroglycerin tolerance in human vessels - evidence for impaired nitroglycerin bioconversion. Circulation 102 23 (2000) 2810-2815
323. Saini H.K., and Dhalla N.S. Defective calcium handling in cardiomyocytes isolated from hearts subjected to ischemia-reperfusion. Am J Physiol 288 5 (2005) H2260-2270
324. Saito T., Fukuzawa J., Osaki J., Sakuragi H., Yao N., Haneda T., Fujino T., Wakamiya N., Kikuchi K., and Hasebe N. Roles of calcineurin and calcium/calmodulin-dependent protein kinase II in pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol 35 9 (2003) 1153-1160
325. Salloum F.N., Abbate A., Das A., Houser J.E., Mudrick C.A., Qureshi I.Z., Hoke N.N., Roy S.K., Brown W.R., Prabhakar S., and Kukreja R.C. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol 294 3 (2008)
326. Sangaralingham S.J., Tse M.Y., and Pang S.C. Estrogen protects against the development of salt-induced cardiac hypertrophy in heterozygous proANP gene-disrupted mice. J Endocrinol 194 1 (2007) 143-152
327. Sauro M.D., and Fitzpatrick D.F. Atrial natriuretic peptides inhibit protein kinase C activation in rat aortic smooth muscle. Pept Res 3 3 (1990) 138-141
328. Sawyer D.B., Siwik D.A., Xiao L., Pimentel D.R., Singh K., and Colucci W.S. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34 4 (2002) 379-388
329. Schafer A., and Bauersachs J. Therapeutic targets of ataciguat. Drug Future 32 8 (2007) 731-738
330. Schermuly R.T., Stasch J.P., Pullamsettl S.S., Middendorff R., Muller D., Schluter K.D., Dingenclorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., Ghofrani H.A., and Grirnminger F. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Resp J 32 4 (2008) 881-891
331. Scheuer J. Catecholamines in cardiac hypertrophy. Am J Cardiol 83 12A (1999) 70H-74H
332. Schindler U., Strobel H., Schonafinger K., Linz W., Lohn M., Martorana P.A., Rutten H., Schindler P.W., Busch A.E., Sohn M., Topfer A., Pistorius A., Jannek C., and Mulsch A. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol. Pharmacol. 69 4 (2006) 1260-1268
333. 3 receptor and cGMP kinase I beta. Nature 404 6774 (2000) 197-201
334. Schmidt H., Lohmann S.M., and Walter U. The nitric oxide and cGMP signal transduction system - regulation and mechanism of action. Biochim Biophys Acta 1178 2 (1993) 153-175
335. Schmidt P.M., Schramm M., Schroder H., Wunder F., and Stasch J.P. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279 4 (2004) 3025-3032
336. Schneider M.P., Klingbeil A.U., Delles C., Ludwig M., Kolloch R.E., Krekler M., Stumpe K.O., and Schmieder R.E. Effect of irbesartan versus atenolol on left ventricular mass and voltage - results of the Cardio Vascular Irbesartan Project. Hypertension 44 1 (2004) 61-66
337. Schrammel A., Behrends S., Schmidt K., Koesling D., and Mayer B. Characterization of 1H-[1,2,4]oxadiazolo 4,3-a quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50 1 (1996) 1-5
338. Schulz E., Tsilimingas N., Rinze R., Reiter B., Wendt M., Oelze M., Woelken-Weckmuller S., Walter U., Reichenspurner H., Meinertz T., and Munzel T. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105 (2002) 1170-1175
339. 2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. J Biol Chem 283 36 (2008) 24412-24419
340. Seki T., Naruse M., Naruse K., Yoshimoto T., Tanabe A., Seki M., Tago K., Imaki T., Demura R., and Demura H. Induction of heme oxygenase produces load-independent cardioprotective effects in hypertensive rats. Life Sci 65 (1999) 1077-1086
341. Selemidis S., Dusting G.J., Peshavariya H., Kemp-Harper B.K., and Drummond G.R. Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc Res 75 2 (2007) 349-358
342. Selemidis S., Sobey C.G., Wingler K., Schmidt H.H.H.W., and Drummond G.R. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120 3 (2008) 254-291
343. Selvetella G., Hirsch E., Notte A., Tarone G., and Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63 3 (2004) 373-380
344. Selwood D.L., Brummell D.G., Budworth J., Burtin G.E., Campbell R.O., Chana S.S., Charles I.G., Fernandez P.A., Glen R.C., Goggin M.C., Hobbs A.J., Kling M.R., Liu Q., Madge D.J., Meillerais S., Powell K.L., Reynolds K., Spacey G.D., Stables J.N., Tatlock M.A., Wheeler K.A., Wishart G., and Woo C.K. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. J Med Chem 44 1 (2001) 78-93
345. Sha X., Isbell T.S., Patel R.P., Day C.S., and King S.B. Hydrolysis of acyloxy nitroso compounds yields nitroxyl (HNO). J Am Chem Soc 128 30 (2006) 9687-9692
346. Sharma G.D., Nguyen H.T., Antonov A.S., Gerrity R.G., von Geldern T., and Pandey K.N. Expression of atrial natriuretic peptide receptor-A antagonizes the mitogen-activated protein kinases (Erk2 and P38(MAPK)) in cultured human vascular smooth muscle cells. Mol Cell Biochem 233 1-2 (2002) 165-173
347. Shen J.B., and Pappano A.J. On the role of phosphatase in regulation of cardiac L-type calcium current by cyclic GMP. J Pharmacol Exp Ther 301 2 (2002) 501-506
348. Shohet R.V., Kisanuki Y.Y., Zhao X.S., Siddiquee Z., Franco F., and Yanagisawa M. Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc Natl Acad Sci U S A 101 7 (2004) 2088-2093
349. Shubeita H.E., McDonough P.M., Harris A.N., Knowlton K.U., Glembotski C.C., Brown J.H., and Chien K.R. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 265 33 (1990) 20555-20562
350. Simko F., Matuskova J., Luptak I., Pincikova T., Krajcirovicova K., Stvrtina S., Pomsar J., Pelouch V., Paulis L., and Pechanova O. Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Physiol Res 56 Suppl 2 (2007) S25-32
351. Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 72 2 (1983) 732-738
352. Smolenski A., Burkhardt A.M., Eigenthaler M., Butt E., Gambaryan S., Lohmann S.M., and Walter U. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn-Schmied Arch Pharmacol 358 1 (1998) 134-139
353. Soeki T., Kishimoto I., Okumura H., Tokudome T., Horio T., Mori K., and Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 45 4 (2005) 608-616
354. Stasch J.P., and Hobbs A. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 191 (2009) 277-308
355. Stasch J.P., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Minuth T., Perzborn E., Schramm M., and Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135 2 (2002) 333-343
356. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., and Schramm M. NO-independent regulatory site on soluble guanylate cyclase. Nature 410 6825 (2001) 212-215
357. Stasch J.P., Dembowsky K., Perzborn E., Stahl E., and Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135 2 (2002) 344-355
358. Stasch J.P., Schmidt P., Alonso-Alija C., Apeler H., Dembowsky K., Haerter M., Heil M., Minuth T., Perzborn E., Pleiss U., Schramm M., Schroeder W., Schroder H., Stahl E., Steinke W., and Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136 5 (2002) 773-783
359. Stasch J.P., Schmidt P.M., Nedvetsky P.I., Nedvetskaya T.Y., Kumar A., Meurer S., Deile M., Taye A., Knorr A., Lapp H., Muller H., Turgay Y., Rothkegel C., Tersteegen A., Kemp-Harper B., Muller-Esterl W., and Schmidt H.H.H.W. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116 9 (2006) 2552-2561
360. Stein A.B., Guo Y., Tan W., Wu W.J., Zhu X., Li Q., Luo C., Dawn B., Johnson T.R., Motterlini R., and Bolli R. Administration of a CO-releasing molecule at the time of reperfusion reduces infarct size in vivo. J. Mol. Cell. Cardiol. 38 (2005) 127-134
361. Stone J.R., and Marletta M.A. Soluble guanylate cyclase from bovine lung: activation with nitric oxide and carbon monoxide and spectral characterization of the ferrous and ferric states. Biochemistry 33 18 (1994) 5636-5640
362. Stumpe T., Decking U.K., and Schrader J. Nitric oxide reduces energy supply by direct action on the respiratory chain in isolated cardiomyocytes. Am J Physiol 280 5 (2001) H2350-2356
363. Su J., Scholz P.M., and Weiss H.R. Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med 230 4 (2005) 242-250
364. Suga S., Itoh H., Komatsu Y., Ogawa Y., Hama N., Yoshimasa T., and Nakao K. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells-evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 133 6 (1993) 3038-3041
365. Sugimoto T., Haneda M., Togawa M., Isono M., Shikano T., Araki S., Nakagawa T., Kashiwagi A., Guan K.L., and Kikkawa R. Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells. J Biol Chem 271 1 (1996) 544-547
366. Suhasini M., Li H.E., Lohmann S.M., Boss G.R., and Pilz R.B. Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway. Mol Cell Biol 18 12 (1998) 6983-6994
367. Supowit S.C., Rao A., Bowers M.C., Zhao H.W., Fink G., Steficek B., Patel P., Katki K.A., and DiPette D.J. Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 45 1 (2005) 109-114
368. Swynghedauw B. Phenotypic plasticity of adult myocardium: molecular mechanisms. J Exp Biol 209 Pt 12 (2006) 2320-2327
369. Sydow K., Daiber A., Oelze M., Cheng Z., August M., Wendt M., Ullrich V., Mulsch A., Schulz E., Keaney J.F., Stamler J.S., and Munzel T. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113 3 (2004) 482-489
370. Takagi G., Kiuchi K., Endo T., Yamamoto T., Sato N., Nejima J., and Takano T. α-Human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs. J Cardiovasc Pharmacol 36 1 (2000) 22-30
371. Takahashi N., Saito Y., Kuwahara K., Harada M., Kishimoto I., Ogawa Y., Kawakami R., Nakagawa Y., Nakanishi M., and Nakao K. Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 26 10 (2003) 847-853
372. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 10 (2001) 1429-1437
373. Takimoto E., Champion H.C., Li M.X., Belardi D., Ren S.X., Rodriguez E.R., Bedja D., Gabrielson K.L., Wang Y.B., and Kass D.A. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 2 (2005) 214-222
374. Tanaka K., Honda M., and Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 37 2 (2001) 676-685
375. Teixeira C.E., Priviero F.B.M., and Webb R.C. Effects of 5-Cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyr imidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice. J Pharmacol Exp Ther 322 3 (2007) 1093-1102
376. Temsah R., and Nemer M. GATA factors and transcriptional regulation of cardiac natriuretic peptide genes. Regul Pept 128 3 (2005) 177-185
377. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther 10 6 (1997) 735-742
378. 2+ cycling. Circ Res 100 1 (2007) 96-104
379. Tokudome T., Horio T., Kishimoto I., Soeki T., Mori K., Kawano Y., Kohno M., Garbers D.L., Nakao K., and Kangawa K. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides. Circulation 111 23 (2005) 3095-3104
380. Tokudome T., Horio T., Soeki T., Mori K., Kishimoto I., Suga S.I., Yoshihara F., Kawano Y., Kohno M., and Kangawa K. Inhibitory effect of C-type natriuretic peptide (CNP) on cultured cardiac myocyte hypertrophy: interference between CNP and endothelin-1 signaling pathways. Endocrinology 145 5 (2004) 2131-2140
381. Tokudome T., Kishimoto I., Horio T., Arai Y., Schwenke D.O., Hino J., Okano I., Kawano Y., Kohno M., Miyazato M., Nakao K., and Kangawa K. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 117 18 (2008) 2329-2339
382. Tongers J., Fiedler B., König D., Kempf T., Klein G., Heineke J., Kraft T., Gambaryan S., Lohmann S.M., Drexler H., and Wollert K.C. Heme oxygenase-1 inhibition of MAP kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes. Cardiovasc Res 63 3 (2004) 545-552
383. Traore K., Sharma R., Thimmulappa R.K., Watson W.H., Biswal S., and Trush M.A. Redox-regulation of Erk1/2-directed phosphatase by reactive oxygen species: role in signaling TPA-induced growth arrest in ML-1 cells. J Cell Physiol 216 1 (2008) 276-285
384. Tsou P.S., Addanki V., Haas J.A., Page N.A., and Fung H.L. Role of glutaredoxin-mediated protein S-glutathionylation in cellular nitroglycerin tolerance. J Pharmacol Exp Ther 329 2 (2009) 649-656
385. Tsoutsman T., Bagnall R.D., and Semsarian C. Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure. Clin Exp Pharmacol Physiol 35 11 (2008) 1349-1357
386. Tziros C., and Freedman J.E. The many antithrombotic actions of nitric oxide. Curr. Drug Targets 7 10 (2006) 1243-1251
387. Urbanek K., Quaini F., Tasca G., Torella D., Castaldo C., Nadal-Ginard B., Leri A., Kajstura J., Quaini E., and Anversa P. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci U S A 100 18 (2003) 10440-10445
388. Vaandrager A.B., Hogema B.M., and de Jonge H.R. Molecular properties and biological functions of cGMP-dependent protein kinase II. Frontiers Biosci 10 (2005) 2150-2164
389. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 3 (2001) 334-341
390. van Rooij E., Doevendans P.A., Crijns H.J., Heeneman S., Lips D.J., van Bilsen M., Williams R.S., Olson E.N., Bassel-Duby R., Rothermel B.A., and De Windt L.J. MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. Circ Res 94 3 (2004) e18-e26
391. van Wamel A.J., Ruwhof C., van der Valk-Kokshoom L.E., Schrier P.I., and van der Laarse A. The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 218 1-2 (2001) 113-124
392. Vieira H.L., Queiroga C.S., and Alves P.M. Pre-conditioning induced by carbon monoxide provides neuronal protection against apoptosis. J Neurochem 107 2 (2008) 375-384
393. Vellaichamy E., Kaur K., and Pandey K.N. Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides 28 4 (2007) 893-899
394. Verdecchia P., Angeli F., Borgioni C., Gattobigio R., de Simone G., Devereux R.B., and Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 16 11 (2003) 895-899
395. Villar I.C., Panayiotou C.M., Sheraz A., Madhani M., Scotland R.S., Nobles M., Kemp-Harper B., Ahluwalia A., and Hobbs A.J. Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 74 3 (2007) 515-525
396. Wang R., and Wu L. The chemical modification of KCa channels by carbon monoxide in vascular smooth muscle cells. J Biol Chem 272 (1997) 8222-8226
397. Wang Y., de Waard M.C., Sterner-Kock A., Stepan H., Schultheiss H.P., Duncker D.J., and Walther T. Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 9 6-7 (2007) 548-557
398. Wanstall J.C., Jeffery T.K., Gambino A., Lovren F., and Triggle C.R. Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br J Pharmacol 134 (2001) 463-472
399. Watzinger N., Maier R., Reiter U., Reiter G., Fuernau G., Wonisch M., Fruhwald F.M., Schumacher M., Zweiker R., Rienmueller R., and Klein W. Clinical applications of cardiovascular magnetic resonance. Curr Pharm Des 11 4 (2005) 457-475
400. Weisbrod R.M., Griswold M.C., Yaghoubi M., Komalavilas P., Lincoln T.M., and Cohen R.A. Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol 125 8 (1998) 1695-1707
401. Wenzel P., Hink U., Oelze M., Schuppan S., Schaeuble K., Schildknecht S., Ho K.K., Weiner H., Bachschmid M., Munzel T., and Daiber A. Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem 282 1 (2007) 792-799
402. Wettschureck N., Rutten H., Zywietz A., Gehring D., Wilkie T.M., Chen J., Chien K.R., and Offermanns S. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7 11 (2001) 1236-1240
403. Wollert K.C., Fiedler B., Gambaryan S., Smolenski A., Heineke J., Butt E., Trautwein C., Lohmann S.M., and Drexler H. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39 1 (2002) 87-92
404. Worthley M.I., Holmes A.S., Willoughby S.R., Kucia A.M., Heresztyn T., Stewart S., Chirkov Y.Y., Zeitz C.J., and Horowitz J.D. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes - mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 49 3 (2007) 304-310
405. Worthley M.I., Horowitz J.D., and Zeitz C.J. Lack of inotropic effect of nitric oxide on the rat myocardium. Clin Exp Pharmacol Physiol 32 7 (2005) 526-530
406. Xia Z., Kuo K.H., Nagareddy P.R., Wang F., Guo Z., Guo T., Jiang J., and McNeill J.H. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 73 4 (2007) 770-782
407. Xu J., Gong N.L., Bodi I., Aronow B.J., Backx P.H., and Molkentin J.D. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem 281 14 (2006) 9152-9162
408. Yang J., Clark J.W., Bryan R.M., and Robertson C.S. Mathematical modeling of the nitric oxide/cGMP pathway in the vascular smooth muscle cell. Am J Physiol 289 2 (2005) H886-H897
409. Yet S.F., Tian R., Layne M.D., Wang Z.Y., Maemura K., Solovyeva M., Ith B., Melo L.G., Zhang L., Ingwall J.S., Dzau V.J., Lee M.E., and Perrella M.A. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 89 (2001) 168-173
410. Yoshimura M., Yasue H., Morita E., Sakaino N., Jougasaki M., Kurose M., Mukoyama M., Saito Y., Nakao K., and Imura H. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
411. Yu S.M., Hung L.M., and Lin C.C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95 5 (1997) 1269-1277
412. Yugar-Toledo J.C., Ferreira-Melo S.E., Consolim-Colombo F.M., Irigoyen M.C., Coelho O.R., and Moreno H. Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. Nitric Oxide 16 3 (2007) 315-321
413. Zanfolin M., Faro R., Araujo E.G., Guaraldo A.M.A., Antunes E., and De Nucci G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol 47 3 (2006) 391-395
414. Zhang J., Chen Z., Cobb F.R., and Stamler J.S. Role of mitochondrial aldehyde dehydrogenase in nitroglycerin-induced vasodilation of coronary and systemic vessels: an intact canine model. Circulation 110 6 (2004) 750-755
415. Zhang Q., Kohara K., Qui H.Y., and Hiwada K. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Ther 4 5-6 (1997) 199-202
416. Zhang M., Koitabashi N., Nagayama T., Rambaran R., Feng N., Takimoto E., Koenke T., O'Rourke B., Champion H.C., Crow M.T., and Kass D.A. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal 20 12 (2008) 2231-2236
417. Zhang G.X., Ohmori K., Nagai Y., Fujisawa Y., Nishiyama A., Abe Y., and Kimura S. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 42 4 (2007) 804-811
418. Zhao Y., Brandish P.E., DiValentin M., Schelvis J.P., Babcock G.T., and Marletta M.A. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39 35 (2000) 10848-10854